No Data
No Data
No Data
No Data
No Data
Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement From EnVVeno Medical's VenoValve(R) Pivotal Trial to Be Presented Today at the 46th Annual Charing Cross Symposium
Overall 8.46 Average Revised Venous Clinical Severity Score (rVCSS) Improvement Per Patient for Patients Showing Clinical Meaningful Benefit (rVCSS Improvement ≥ 3 Points) including:9.29 Points for Pa
AccesswireApr 24 06:15 ET
Express News | New Topline Efficacy Data From EnVVeno Medical VenoValve Pivotal Trial To Be Presented At 46th Annual Charing Cross Symposium On April 24, 2024
Moomoo 24/7Apr 16 09:09 ET
New Topline Efficacy Data From the EnVVeno Medical VenoValve(R) Pivotal Trial to Be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024
IRVINE, CA / ACCESSWIRE / April 16, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today an
AccesswireApr 16 09:00 ET
EnVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer
Appointment bolsters Company's transition from being a clinical stage to a commercial entity planning for the monetization of the VenoValvePMA application seeking FDA approval for the VenoValve on track to be filed
AccesswireApr 9 08:45 ET
EnVVeno Medical(NVNO.US) Officer Sells US$51,837.48 in Common Stocks
$enVVeno Medical(NVNO.US)$ Officer Alavi Hamed sold 8,334 shares of Common Stocks on Mar 13, 2024 at an average price of $6.22 for a total value of $51,837.48.Source: Announcement What is statement of
moomoo NewsMar 15 20:40 ET
EnVVeno Medical to Participate in the Virtual Investor Lunch Break: The EnVVeno Opportunity
Live video webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Thursday, March 21st at 12:00 PM ETIRVINE, CA / ACCESSWIRE / March 15, 2024 / enVVeno Medical Corporation
AccesswireMar 15 09:00 ET
No Data
No Data